Drug eluting stents: Focus on Cypher™ sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions by Chieffo, Alaide et al.
© 2007 Dove Medical Press Limited.   All rights reserved
Vascular Health and Risk Management 2007:3(4) 441–451 441
REVIEW
Drug eluting stents: Focus on Cypher™ sirolimus-
eluting coronary stents in the treatment of 
patients with bifurcation lesions
Alaide Chieffo
Tiziana Claudia Aranzulla
Antonio Colombo
Interventional Cardiology Unit, San 
Raffaele Scientific Institute, Milan, Italy
Correspondence:  Antonio Colombo
San Raffaele Hospital, Via Olgettina 62, 
20132 Milan, Italy
Tel + 39 022 643 7331
Fax + 39 022 643 7339
Email colombo.antonio@hsr.it
Abstract: Coronary bifurcations represent a challenging lesions subset and account for up 
to 15% of all current PCI. Regardless of the stenting technique used, however, restenosis rate 
after bare metal stent (BMS) is high, especially at the ostium of the side branch (SB). The 
introduction of drug-eluting stent (DES) has remarkably improved the outcome in bifurcation 
lesions compared to BMS, resulting in lower adverse events and main branch (MB) restenosis 
rates. Furthermore, although the “provisional” stenting technique (second stent on the SB 
placed, after the MB stenting, only in case of suboptimal or inadequate result) remained the 
prevailing approach, several two-stent techniques emerged (crush) or were re-introduced (V, 
T, culottes) to allow stenting in both branches when needed. At the present time, only few ran-
domized studies and some observational reports speciﬁ  cally addressed the issue of bifurcation 
lesion treatment with sirolimus-eluting stents (SES). It is still not clear yet which is the better 
strategy between the provisional approach and stenting both branches when dealing with a 
bifurcation lesion which has a stenosis in the SB suitable for stenting. Moreover, no study has 
so far addressed which is the best strategy to use among the several techniques reported in the 
literature when both branches are intentionally stented from the outset. Finally, the introduction 
of dedicated stents for different types of bifurcations, with speciﬁ  c stent designs to provide good 
deliverability, secured access to the side branch, complete coverage of the lesion site without 
double/triple layers of stent struts, thus incorporating the beneﬁ  ts of drug elution and ensuring 
drug availability to all diseased surfaces, may further facilitate the conquest of one of the most 
challenging areas in interventional cardiology.
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Introduction
Following the introduction of drug eluting stents (DES), there has been a major shift 
in the management of complex lesions from surgery to percutaneous coronary inter-
vention (PCI). (Colombo and Iakovou 2004a, 2004b; Kastrati et al 2004) Coronary 
bifurcations account for up to 15% of all current PCI (Melikian et al 2004) and still 
represent a challenging lesion subset for the interventional cardiologist. In the stent 
era, despite improved and more predictable acute angiographic results and procedural 
outcomes, (Aliabadi et al 1997; Al Suwaidi et al 2000; Sheiban et al 2000) bifurcation 
treatment was still associated with lower procedural success and higher in-hospital 
major adverse cardiac event (MACE) and restenosis rate, when compared with non 
bifurcation interventions (Lefevre et al 2000; Al Suwaidi et al 2001). Several stent-
ing techniques have been proposed for the treatment of bifurcations (Colombo et al 
1993; Schampaert et al 1996; Chevalier et al 1998; Kobayashi et al 1998; Yamashita 
et al 2000; Lefevre et al 2001; Pan et al 2002). However, regardless of the tech-
nique used, the restenosis rate after bare metal stent (BMS) implantation was high 
(40% to 60%), especially at the ostium of the side branch (SB) (Al Suwaidi et al Vascular Health and Risk Management 2007:3(4) 442
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Figure 1 Current practise in the treatment of bifurcation lesions in our Center.
2000; Yamashita et al 2000; Cervinka et al 2002; Gobeil 
et al 2002). Moreover, regardless of a superior immediate 
angiographic result, BMS implantation in both branches 
offered no additional advantage over main branch (MB) 
stenting alone, in terms of restenosis and re-intervention, 
and was associated with an increase in the occurrence of 
in-hospital MACE (13% vs 0% in the study by Yamashita 
et al) (Al Suwaidi et al 2000; Sheiban et al 2000; Yamashita 
et al 2000; Cervinka et al 2002; Gobeil et al 2002).
The introduction of DES has markedly improved the 
outcome in bifurcation lesions as compared to BMS, resulting 
in lower adverse events and restenosis rates (Colombo et al 
2004; Pan et al 2004; Ge et al 2005b; Tanabe et al 2004). 
Furthermore, although the “provisional” stenting technique 
(second stent on the SB placed after the MB stenting, 
only in case of suboptimal result or complication in side 
branch) remained the prevailing approach, several two-stent 
techniques emerged (crush) or were re-introduced (V, T, 
culottes) (Iakovou et al 2005a). In our experience (Figure 1) 
the provisional stent approach is in general the preferred 
one when the SB diameter is less than 2.25 mm and it is 
not diffusely diseased (Iakovou et al 2005a). Conversely, 
stenting of both branches as intention-to-treat, is preferred 
in true bifurcations with a diffusely diseased SB  2.25 mm 
in diameter.
Sirolimus-eluting stent in the 
treatment of bifurcation lesions
At the present time, only few randomized studies and some 
observational reports speciﬁ  cally addressed the issue of bifur-
cation lesion treatment with sirolimus-eluting stents (SES).
Randomized studies evaluating SES 
in bifurcation lesions
The safety and efﬁ  cacy of SES for the treatment of de novo 
true bifurcation lesions has been evaluated in three random-
ized studies. All compared the systematic use of two stents 
versus a provisional side-branch stenting strategy.
In the ﬁ  rst prospective multicenter study, (Colombo et al 
2004) 85 patients with 86 bifurcation lesions were randomly 
assigned to Cypher (Cordis Corp, a Johnson & Johnson 
Company, Warren, New Jersey) stent implantation either in 
both branches as intention to treat (group A) or in the MB 
only, with provisional SB stenting (group B). Twenty-two 
patients crossed over from group B to group A (51.2%) due 
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to suboptimal result after balloon dilatation of the SB, and 
2 patients crossed over from group A to group B (4.7%) due 
to lack of successful stent delivery in the SB. Analysis was 
performed according to the actual treatment received (not 
by intention-to-treat) and because of the high crossover rate 
more lesions were treated with stenting of both branches 
(n = 63) than with MB stent/SB balloon (n = 22). One patient 
died suddenly 4.5 months after the procedure; three (3.5%) 
had stent thrombosis (in 2 cases involving the SB and both 
branches in the other). All patients with stent thrombosis, as 
well as the patient that died suddenly, had undergone stenting 
of both branches. The total 6-month in-segment restenosis 
rate per lesion (either SB or MB or both) was 25.7%, not 
signiﬁ  cantly different between groups A (28.0%) and B 
(18.7%). Most restenoses were focal and occurred at the SB 
ostium. Target lesion revascularization (TLR) was performed 
in 7 cases overall. Three of the 4 intravascular ultrasound 
(IVUS) examinations performed at follow-up among the 
11 cases of SB in-stent restenosis demonstrated incomplete 
ostium coverage by the stent struts.
The main ﬁ  ndings of this study were: 1) the remarkably 
lower restenosis rate in the MB with the use of Cypher™ 
stent (6.1%) as compared with historical BMS controls; 
2) the frequent residual stenosis at the SB ostium after bal-
loon angioplasty, leading to a high rate (51.2%) of cross 
over to additional SB stenting; 3) the absence of a clear 
superiority of systematic SB stenting as compared to MB 
stenting only; 4) the relatively high angiographic restenosis 
rates occurring at SB (mostly located at the ostium) when an 
additional Cypher stent was implanted there, and, conversely, 
the low TLR rate (7 of 17 cases), probably reﬂ  ecting a limited 
clinical importance of many cases of angiographic SB reste-
nosis; 5) the 3.5% stent thrombosis rate, higher than previ-
ously experienced with Cypher stent in less complex lesions. 
Because of the high crossover rate in this study, no conclu-
sions could be drawn regarding the most appropriate bifurca-
tion stenting technique. However, the study highlighted the 
persistent limitations of routine SB stenting that although 
results are improved compared with historical BMS data; SB 
restenosis albeit focal continues to remain a problem.
In the study by Pan et al (Pan et al 2004) 91 patients with 
true bifurcation lesions, all receiving a SES in the MB, were 
randomly assigned to either balloon dilation of the involved 
SB (group A; n = 47) or a second stent in the SB (group 
B; n = 44). Crossover was allowed only in patients with 
severe persistent stenosis and/or major ﬂ  ow-limiting dissec-
tions; local dissections with TIMI 3 ﬂ  ow were left without 
additional treatment. According to this predeﬁ  ned criteria for 
additional stenting, crossover rates were relatively low: only 
1 patient from group A to SB stenting and 4 patients from 
group B to A. Primary success was obtained in 44 patients 
of group A (94%) and 43 of group B (97%). At 6 month 
follow-up, MACE occurred in 3 patients in group A: 2 had 
in-hospital non-Q–wave myocardial infarction (MI) and 1 
TLR and in 3 patients in group B: 1 experienced a 15 day 
post-procedure sub-acute stent thrombosis, followed by MI 
and eventual death, and 2 TLR. Six-month angiographic fol-
low-up was performed in 80 (88%) patients. MB restenosis 
occurred in 1 (2%) patient in group A and 4 (10%) in group 
B; SB restenosis occurred in 2 (5%) patients in group A and 6 
(15%) in group B. Therefore, similar to the Sirius bifurcation 
study,(Colombo et al 2004) stenting both branches seemed 
to provide no advantage over a provisional strategy and once 
again was associated with a higher SB restenosis rate.
Steigen et al (Steigen et al 2006) recently published the 
results of the Nordic Bifurcation Study which included 413 
patients with a bifurcation lesion randomized to stenting 
of both branches (n = 206), with “crush”, “culottes”, “Y” 
or other techniques, or provisional SB stenting (n = 207) 
with SES implantation. The crossover from provisional to 
double branch stenting was allowed only if following SB 
dilation TIMI ﬂ  ow was 0. However, SB dilation was only 
performed if TIMI  3 ﬂ  ow in the SB. Procedural success 
was achieved in 97% of cases in the provisional and 95% in 
the both branches stenting group. The SB was stented only in 
4.3% of cases in the provisional stenting group. Final kissing 
balloon inﬂ  ation (FKB) was performed in 32% of the cases 
in the provisional group and 74% of double stenting group 
(p   0.001). At 6 months, no statistical difference between 
the two groups was found in the primary end-point of MACE 
(2.9% in the MV group and 3.4% in the MV + SB group). 
No differences were also detected in any of the primary end-
point components (death, MI, TVR, or stent thrombosis). 
Procedure-related biomarker release could be evaluated in 
279 patients (126 patients in the MV + SB group and 153 
in the MV group). Marker elevation of  3 times the upper 
limit of normal was seen in 18% of MV + SB and in 8% of 
MV group (p = 0.011). At randomization, only 358 out of 
413 patients enrolled in this trial, were scheduled for 8-month 
follow-up angiography. Complete angiographic evaluation 
was available, indeed, in 307 patients (86%) of these, 151 
patients were randomized to the MV group and 156 to the 
MV + SB group. The combined angiographic end point of 
diameter stenosis  50% of main vessel and/or occlusion of 
the side branch after 8 months was found in 8 patients (5.3%) 
in the MV group and 8 patients (5.1%) in the MV + SB group Vascular Health and Risk Management 2007:3(4) 444
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(p = 0.96). The main limitation of this study was the lack of 
systematic angiographic follow-up (only 76% of the total 
number of patients randomized did angiographic follow-up). 
It is well known that most restenoses occurring at the SB 
ostium are clinically silent and thus not detected, unless 
identiﬁ  ed at follow-up angiography. The effective clinical 
value of these silent restenosis is currently unknown.
Observational studies
Ge et al (Ge et al 2005b) evaluated the one vs. two stent ap-
proach in 174 consecutive patients with bifurcation lesions, 
treated with a SB provisional (group 1S; 57 patients with 
58 bifurcation lesions) or both branches (group 2S; 117 
patients with 126 bifurcation lesions) SES implantation 
strategy. In-hospital MACE were respectively 8.8% in the 
1S and 10.3% in the 2S group (p = 0.97). At 9 months, no 
signiﬁ  cant differences in terms of MB and SB restenosis, 
TLR (5.4% vs 8.9%, p = 0.76), target vessel revascular-
ization (TVR, 5.4% vs 11.1%, p = 0.51) or cumulative 
MACE (18.9% vs 23.3%, p = 0.76) were found between 
the 2 groups. Conﬁ  rming previous data, this study showed 
a high procedural success irrespective of the technique 
used, with marked improvement compared to historical 
controls with BMS.
At that time, the T- and modiﬁ  ed T-stenting techniques 
were used as the default two-stent strategies. However, an 
important limitation of these approaches is represented by 
the inability to guarantee full SB ostium coverage, espe-
cially in cases with a narrow bifurcation angle. There is 
almost always a small gap left between the MB and the SB 
stents, as shown in 2/3 of the SB restenosis cases examined 
by IVUS in the sirolimus bifurcation study (Colombo et al 
2004). Furthermore, when DES are implanted, incomplete 
SB ostium coverage with consequent lack of drug delivery 
could be a factor contributing to the occurrence of restenosis 
at this site.
Crush technique
The need for a 2-stent technique to overcome the limita-
tions of T-stenting and guarantee full SB ostium coverage 
prompted our group to develop the “crush” technique. 
This strategy reproduces the same steps of the modified-
T stenting, with the main difference being a slight (3–4 
mm) protrusion of the proximal edge of the SB stent into 
the MB (Iakovou et al 2005a). The SB stent is then flat-
tened against the MB stent. Our initial experience with 
the crush technique involved 20 patients with true bifur-
cation lesions treated with SES implantation (Colombo 
et al 2003) (Airoldi et al 2003). In order to correct stent 
deformation and improve strut contact to the vessel wall, 
and thus better drug delivery to the SB ostium, (Ormiston 
et al 2004) FKB was implemented as part of the crush 
technique, which was not routinely performed in our 
preliminary experience. FKB, which was not routinely 
performed in our preliminary experience, was imple-
mented as part of the crush technique in order to correct 
stent deformation, improve strut contact to the vessel wall, 
and thus better drug delivery to the SB ostium.
Ge et al (Ge et al 2005a) evaluated the long-term 
outcome after SES or paclitaxel-eluting stent (PES) 
implantation in true bifurcations treated with the “crush” 
technique performed with or without FKB, according to 
operator’s discretion. SB restenosis and late lumen loss 
were significantly lower in lesions treated with FKB, as 
compared to those without (11.1% vs 37.9%, p   0.001). 
The cumulative MACE rate was also lower in the FKB 
group (19.8% vs 38.5%, p = 0.008). The absence of FKB 
was identified as an independent predictor (HR 4.17, 
p = 0.02) of TLR. In this study, the “crush” stenting 
technique with FKB was associated with more favour-
able long-term outcomes, with a striking 49% reduction 
in SB restenosis rates as compared to the SES bifurcation 
study, (Colombo 2004) probably due to better strut cover-
age of and drug delivery to the vessel wall. Furthermore, 
whenever restenosis occurred, it was focal ( 5 mm in 
length), located at the SB ostium (75.0%), and majority of 
the time was not associated with symptoms or ischemia. 
These results demonstrated that FKB is a mandatory step 
of the “crush” technique.
An important technical aspect that we recommend regard-
ing the ﬁ  nal dilation is the performance of a high-pressure SB 
inﬂ  ation before the ﬁ  nal kissing balloon inﬂ  ation. This 2-step 
ﬁ  nal kissing inﬂ  ation results in improved opening of and less 
obstruction by stent struts at the side branch ostium.
Moussa et al (Moussa 2006) reported in a prospective 
registry on the outcome of 120 patients with de novo or 
in-BMS restenotic bifurcation lesions, treated with SES 
using the “crush” technique. FKB was performed in 87.5% 
of cases. Procedural as well as device success was achieved 
in 97.5% (3 patients received a BMS in the SB because of 
SES inability to cross the lesion). No in-hospital MACE was 
reported. At 30 days, stent thrombosis occurred in 2 patients 
(1.7%), one was treated with repeat PCI and the other was 
referred for coronary artery bypass graft (CABG) surgery. 
At 6 months, no cardiac death, MI or stent thromboses 
were reported. TLR was required in 13 patients (11.3%): Vascular Health and Risk Management 2007:3(4) 445
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10 (8.7%) underwent rePCI and 3 (2.6%) were referred 
to CABG. Restenosis was focal in all cases involving the 
MB only in 3 patients (23%), the SB ostium and the MB in 
1 patient (8%), and limited to the SB ostium in 9 patients 
(69%). These ﬁ  ndings conﬁ  rmed that, when appropriately 
performed, the crush technique is safe and associated with 
a low incidence of early or late thrombosis. However, even 
if reduced following routine FKB, restenosis is still present, 
especially at the SB ostium.
Possible explanations of SB ostial restenosis might be 
the breakage of the polymer secondary to the overlap of 
multiple struts layers, stent deformation or stent under 
expansion.(Ormiston et al 2004) IVUS studies have 
shown that stent dimensions are important predictors of 
restenosis even with DES (Sonoda et al 2004) and that 
imaging of both branches could reveal inadequate stent 
expansion in at least one branch even after kissing bal-
loon inflation and regardless of the angiographic result 
(Takebayashi et al 2003).
Costa et al (Costa et al 2005) reported IVUS find-
ings in 40 patients with bifurcation lesions treated with 
“crush” technique and SES. Post-intervention IVUS was 
performed in both branches in 25 lesions and only in the 
MB in 15 lesions. IVUS measurements were performed in 
the proximal stent, crush area and distal stent in the MB 
as well as in the ostium and distal stent in the SB. Over-
all; minimum stent area (MSA) was larger in the MB as 
compared to the SB (6.7 ± 1.7 mm2 vs 4.4 ± 1.4 mm2, p   
0.0001, respectively). When only the MB was considered, 
the MSA was smaller in the crush area (rather than in the 
proximal or distal stent segments) in 56% of the lesions. 
However, when both the MB and the SB were considered, 
the smallest MSA was calculated in the SB ostium in 68% 
of cases. In the lesions not involving the left main coro-
nary artery (LMCA), stent expansion was significantly 
lower in the SB as compared to the MB (p = 0.02). The 
MB MSA measured  4 mm2 in 8% of lesions and  5 
mm2 in 20%. For the SB, a MSA  4 mm2 was found in 
44%, and a MSA  5 mm2 in 76%, typically at the ostium. 
“Incomplete crushing” (defined as incomplete apposition 
of SB or MB stent struts against the MB wall proximal to 
the carina) was observed in  60% of angiographically 
successful non-LMCA lesions and it was correlated with 
SB stent underexpansion (77.1 ± 7.6% vs 89.4 ± 13.1%, 
p = 0.04). The only patient with subacute stent thrombosis 
had incomplete crushing. Despite the wide (80% of cases) 
use of SB ostial predilation and FKB (performed in all 
but 2 cases), stent underexpansion and incomplete strut 
apposition in the “crush area” were detected by IVUS. 
The location of the smallest MSA at the SB ostium could 
explain the higher restenosis rate at this site. The results 
of this study emphasize the value of performing a full and 
complete high pressure post-dilation of the SB stent.
Different stenting techniques
Tanabe et al (Tanabe et al 2004) reported on the outcome 
of a small series of 58 patients with 65 de novo bifurca-
tions, part of the “Rapamycin-Eluting Stent Evaluation At 
Rotterdam Cardiology Hospital” (RESEARCH) registry, 
(Lemos et al 2004) treated with SES in both the main and 
the side branches with one of the following techniques: 
T (63%), culottes (8%), kissing stents (3%), or “crush” 
(26%). Kissing balloon inflation was performed in only 
31% of cases. At 6 months, MACE occurred in 10.3% of 
cases, with a TLR rate of 8.6%, and no episodes of MI or 
stent thrombosis. Angiographic 6-month follow-up was 
performed in 44 lesions: restenosis occurred in 10 of them 
(22.7%), and in particular in 4 lesions in the MB (9.1%) 
and in 6 in the SB (13.6%). The restenosis rate for the 
SB was 16.7% following T-stenting vs 7.1% with all the 
other stent techniques. Once again after the use of the T-
stenting technique SB restenosis were mostly located at 
the ostium (5 of the 6 cases of SB restenosis). In a report 
by our group, (Ge et al 2006) the “crush” technique with 
FKB was associated with a significant reduction of SB 
restenosis rate (8.6% vs 26.5%, p = 0.04) when compared 
to the T stenting technique (Figure 2).
No major advantage of the “V” over the “Crush” 
technique was observed in the study by Sawhney et al. 
(Sawhney et al 2005) One hundred-fifty three consecutive 
patients were treated with SES implantation in true bifur-
cation lesions: 102 with “crush” (43 with and 59 without 
FKB) and 51 with the “V” technique. Procedural success 
was achieved in 100% of cases; 18 patients (12%) had 
an in-hospital MI, whereas no death, acute thrombosis or 
urgent TLR was reported. At 5 month follow-up the over-
all TLR rate was 13.1%. The restenosis rate was 13.7% 
in patients treated with “V” stenting, 16.9% in the crush 
group without FKB, and 7.0% in the crush group with 
FKB. Of the 13 TLR that occurred in the crush group, 
most were located at the SB. In the V group 7 TLRs 
occurred, 3 located in one branch and 4 in both branches. 
Three patients (1.9%) experienced subacute thrombosis 
at follow-up and the 9-month cumulative incidence of 
death, MI, TVR or thrombosis was 18%. Bifurcation 
stenting with SES using the “crush” or “V” technique was Vascular Health and Risk Management 2007:3(4) 446
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Figure 2 Restenosis rates and late lumen loss at 6 month angiographic follow-up following double stenting with the “crush” (black bars) vs T stenting (white bars) 
techniques with and without kissing balloon post-dilatation in the main branch (Panel A) and in the side branch (Panel B).  Values are expressed as number (%) or mean 
(SD). NS, not statistical signiﬁ  cant 8 (adapted from Lee et al Heart 2006; 92(3): 371–376)
associated with very low procedural complications and 
acceptably low clinical restenosis rates at 5 months.
Sharma et al evaluated 200 patients who underwent 
SES implantation in 202 true de novo bifurcation lesions 
with the “simultaneous kissing stent” (SKS) technique 
(Sharma 2005). This technique involves implanting a stent 
simultaneously in the MB and SB, which overlap in the 
proximal segment of the MB, thus creating proximally a 
new carina. The SKS differs from the V-technique which 
has a very short or no carina. Procedural success was 
achieved in 100% of the MB and 99% of the SB. In-hos-
pital and 30-day MACE were 3% and 5%, respectively. At 
a mean clinical follow-up of 9 ± 2 months, MI incidence 
was 4% and death rate was 2%. The TLR incidence was 
4%: 6 cases occurred in the SB (3%) and 2 in both SB 
and MB (1%). The isolated SB in-stent restenosis were 
focal, while restenosis involving both SB and MB were 
diffuse. There were two cases (1%) of subacute stent 
thrombosis at day 5 and day 8 but no late stent thrombosis 
was reported.
Jim et al (Jim et al 2006)described the “sleeve tech-
nique”. This technique requires a double kissing balloon 
inflation, before and after MB stenting. The sleeve 
technique was used in 6 consecutive patients with 100% 
success rate and no MACE or stent thrombosis within 
30 days.
Recently a new technique “T And small Protrusion” (TAP 
technique) has been proposed by our group. This technique 
has been used only in 10 cases without adverse cardiac events 
at 30 days; no data at long term are available so far. The TAP 
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technique is mainly used when the operator decides to cross-
over from 1 to 2 stents and consist in the deployment of a 
stent on the SB with a balloon simultaneously inﬂ  ated inside 
the MB stent. The stent in the SB will protrude minimally 
in the MD in order to allow good coverage of the ostium. 
Crush is prevented by keeping SB and MB balloons inﬂ  ated 
simultaneously.
ARTS II substudy
The efﬁ  cacy of SES in bifurcation treatment in patients with 
multivessel coronary artery disease was evaluated in a substudy 
(Tsuchida et al 2007) of the “Arterial Revascularisation Thera-
pies Study Part II” (ARTS II Trial) (Serruys et al 2005).
Compared to non-bifurcation lesions (n = 283), bifurca-
tion lesions (n = 324) were associated with more complex 
procedural characteristics (number of stents implanted, number 
of stented lesions, average and total stent length, GP IIb/IIIa 
inhibitor use, longer procedure times, and post-procedural CK 
elevation), but they were not associated with higher adverse 
event rates at 30 days, as well as at 1 year (Major Adverse 
Cardiac and Cerebral Event, MACCE free survival at 1 year 
90.1% vs 89.2%; p = 0.79). Even the occurrence of stent 
thrombosis did not differ between the bifurcation and the 
non-bifurcation groups (1.2% vs 0.4%; p = 0.38).
Of 465 bifurcation lesions, only 68 lesions (14.6 %) 
in 61 patients were treated with a 2-stent strategy. Despite 
longer procedure duration and complexity, no differences 
were found in 30-day, or 1-year clinical outcomes (1-year 
MACCE free 91.8% vs 88.6%; p = 0.65) in the 2 stent group 
compared with the 1 stent group.
Despite more complex procedural characteristics and 
a higher use of 2 stents, no difference in 30-day or 1-year 
clinical outcome were reported between patients with true 
(Duke modiﬁ  ed Type D, F and G; n = 244 lesions) bifurca-
tions vs. other bifurcation lesion types (n = 221) (Sianos 
et al 2005). Freedom from MACCEs at 1 year was 88.3% 
vs  90.2% respectively (p = 0.60).
SES vs PES
In a study by Pan et al (Pan et al 2007) 205 consecutive 
patients with true bifurcation lesions were randomized to 
SES (n = 103) or PES (n = 102) implantation. At 30 days 1 
patient in the PES group and 2 in the SES group experienced 
a Q-wave MI, and no deaths were reported. At 6 months reste-
nosis (9% vs 29%, p = 0.05) and TLR (4% vs 13 %, p = 0.05) 
rates were signiﬁ  cantly lower in the SES, as compared to 
the PES group. In both groups restenosis occurred mostly 
at SB ostium.
Hoye et al (Hoye et al 2005) evaluated outcomes of 144 
patients treated with SES in 167 de novo bifurcations and 
104 patients treated with PES in 113 bifurcations. At 6 month 
follow-up, MACE-free survival was 93.7% in the SES vs 
85.8% in the PES group (p = 0.05). TLR-free survival was 
95.7% vs. 86.8% (p = 0.01). Predictors of MACE were age, 
diabetes, previous CABG, multivessel disease, treatment 
for acute MI, and treatment with PES. Stent type was the 
only independent predictor of TLR. Neither the baseline 
bifurcation anatomy, nor the stenting technique utilized, 
were predictive of MACE or TLR.
Unanswered questions
1) Optimal treatment strategy 
for bifurcation lesions
At the present time, the optimal strategy for bifurcation treat-
ment is still unclear. Current studies are mostly retrospective, 
involving different bifurcation types (true and non-true bifurca-
tions) and several stenting techniques making any comparison 
not appropriate. In addition, the classiﬁ  cation of bifurcations 
used (Popma et al 1994; Spokojny and Sanborn 1996; Lefevre 
et al 2000; Saﬁ  an 2001) suffer limitations of coronary angiog-
raphy in detection of different plaque distribution and extent 
of disease and do not take into account what happens to the 
SB during the dilatation of the MB (Fujii et al 2003).
Our current practise in bifurcation lesions is illustrated in 
Figure 1. In general, in non-true bifurcations a provisional stent-
ing approach is suggested. In the presence of a true bifurcation 
with a SB larger than 2.25 mm and SB disease localized extend-
ing more than 3 mm from the ostium, elective implantation of 2 
stents is usually required. Conversely, if the SB is smaller than 
2.25 mm with focal disease localized to within 3 mm from the 
ostium a provisional stenting approach is suggested.
Regarding the 2-stent techniques, there are currently no 
data favouring a speciﬁ  c technique. In general, the type of 
stenting technique is decided according to the bifurcation 
angle and extent of disease proximal to the bifurcation: 
V-stenting is preferred when there is no disease proximal to 
the bifurcation; T stenting when the disease extends proximal 
to the bifurcation and the SB has a 90° angle of origin from 
the MB; and ﬁ  nally a crush (or TAP) is suggested when 
the disease extends proximal to the bifurcation and the SB 
originates with a 60° or less angle.
2) Restenosis at the SB ostium
Even with DES, restenosis at the SB ostium remains an im-
portant issue, regardless of the stenting technique employed. Vascular Health and Risk Management 2007:3(4) 448
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The positive aspect is that when it occurs with DES, it is very 
focal ( 5 mm in length) and most of the times not associated 
with signs or symptoms of ischemia.
Costa et al (Costa et al 2005) showed that angiography 
has a the limited ability to detect underexpanded stents 
implanted in bifurcations; consequently, we cannot exclude 
that the impact of SB stent underexpansion is currently 
underestimated, especially in patients with good angiographic 
results of both branches.
In the IVUS substudy of the SIRIUS trial, a MSA  5 mm2 for 
the total cohort and a MSA  4.5 mm2 for vessels  2.8 mm were 
thresholds predicting an “adequate” IVUS lumen at follow-up 
(Sonoda et al 2004) with a positive predictive value of 90%. In 
the study by Costa (Costa et al 2005), MSA  5.0 mm2 was found 
in 80% of non-LM bifurcation lesions, and MSA  4.5 mm2 in 
69% of stents with an mean reference diameter  2.8 mm, in 
both cases mostly in the SB ostium. Thus, MSA was frequently 
below the threshold associated with restenosis, especially at the 
SB ostium. Sub-optimal coverage with stent struts and heteroge-
neous drug delivery are probably potential contributing factors 
to the increased SB ostial restenosis.
3) Stent thrombosis
The multiple layers of stent struts apposed to the vessel wall 
with some of the 2-stent techniques have raised concerns 
about a possible increased risk of stent thrombosis follow-
ing DES implantation (Virmani et al 2004). Conﬂ  icting data 
are presently reported in the literature. Bifurcation lesions 
has been reported to be independent predictors of stent 
thrombosis (Iakovou et al 2005b) (Angiolillo et al 2005). 
Interestingly, in the substudy (Colombo et al 2005) from the 
ARTS 2 study, the occurrence of stent thrombosis did not 
differ between the bifurcation and non-bifurcation groups. In 
the SES bifurcation study (Colombo et al 2004) the overall 
stent thrombosis rate was 3.5%, increasing to 4.6% if the 
patient with sudden death is included and up to 6.3% if only 
the 2-stent group is considered. All thromboses occurred in 
patients taking double antiplatelet therapy, however, the 2 
cases of early thrombosis at day 1 and 3 were associated with 
a clear suboptimal angiographic result (dissection distal to 
the SB stent) and with a lack of GP IIb/IIIa inhibitor treat-
ment. However, it is reassuring that in the Nordic trial, only 
1 episode of deﬁ  nite stent thrombosis occurred and this was 
in a patient treated with 1 stent only (Steigen et al 2006).
Conclusions
The introduction of SES has markedly improved the 
outcomes after the treatment of bifurcation lesions as 
compared to historical BMS controls. However, this subset of 
lesions remains a challenge for the interventional cardiologist 
and is still associated with procedural complications due to 
plaque shift, suboptimal angiographic results, and difﬁ  culty 
in crossing the stent struts, incomplete coverage of the SB 
ostium and, despite DES use, persistence of restenosis, 
especially at the SB ostium.
It is not clear yet which is the optimal stent strategy in this 
subset of lesions. In addition, no study has addressed so far 
which among the different 2 stenting techniques should be the 
preferred when both branches DES implantation is chosen.
Additional information and insights on the efﬁ  cacy and 
safety of the 1-stent versus a speciﬁ  c 2-stent approach in true 
bifurcation lesions will come from the “Coronary bifurcations: 
Application of the Crushing Technique Using Sirolimus-elut-
ing stents” (CACTUS) study. This study has already random-
ized more than 350 patients with de novo bifurcations to either 
a provisional strategy or the crush technique, using CypherTM 
stents. The primary endpoints of the study are in-segment 
restenosis and 6 and 12-month MACE rates.
Finally, the introduction of dedicated DES for different 
bifurcations types may further facilitate the conquest of one 
of the most challenging areas in interventional cardiology. 
These dedicated bifurcation stents are speciﬁ  cally designed to 
provide good deliverability, secured access to the side branch, 
complete coverage of the lesion site without double/triple 
layers of stent struts, and thereby ensuring drug availability 
to all diseased surfaces.
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